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Trends in mortality rates on hemodialysis in Canada, 1981–1997. tices, few previous studies have explicitly examined trends
Significant improvements in hemodialysis (HD) have occurred over time in patient outcomes [14–17]. In order to assess
during recent years. Few previous studies have explicitly exam- whether the above-listed improvements in HD have, inined trends in patient outcomes over time. In order to evaluate
aggregate, resulted in improved survival, we analyzedwhether improvements in HD have resulted in decreased mor-
trends in mortality rates among Canadian end-stage re-tality, we analyzed trends in mortality rates among the 28,700
patients who initiated HD in Canada during the 1981–1997 nal disease (ESRD) patients receiving HD during the
period. Mortality rate ratios (RR) were estimated using Poisson 1981–1997 period.
regression, and adjusted simultaneously for age, race, gender,
primary renal diagnosis and follow-up time. Adjusted mortality
rates decreased significantly by calendar period, with RR 5 METHODS
0.90 (95% CI: 0.83–0.96) for 1990–93 and RR 5 0.74 (0.69–0.80)
Data for all patients initiating therapy between Janu-for 1994–97, relative to 1981–85 (reference; RR 5 1). The
decrease was concentrated in the first two years of follow-up. ary 1, 1981 and December 31, 1997 were obtained from
Among causes of death, mortality due to cardiovascular disease the Canadian Organ Replacement Register (CORR) of
showed the sharpest decline. Among subgroups defined by the Canadian Institute for Health Information (CIHI).
age and diabetes status, mortality improvement was strongest
CORR is a population-based, nation-wide organ failureamong diabetics age ,65 years and weakest among non-diabet-
registry [18]. Coverage is complete in the sense thatics age ,65 years. The observed decreases in HD mortality
could be due to enhancements in dialysis technology, including patient records are submitted annually by each of the
improvements in dialysis machines, water purification systems, 86 renal Canadian centers. Demographic data recorded
dialysate composition, and biocompatibility of dialyzer mem- at the time of initiation of renal replacement therapy
branes. Key roles were likely played by increased attention to
(RRT) include date of birth, gender, province of resi-HD adequacy on the part of clinicians, improved nutrition,
dence, race, predialysis comorbid conditions, and pri-better management of comorbid conditions, and increased
erythropoietin utilization. Detailed data on practice patterns mary renal diagnosis (PRD). RRT data are submitted
are required in order that the degree of association between annually by each center, including dialytic modality
trends in dialysis methodology and mortality may be quantita- switches, transplantations, and graft failures. Where ap-
tively evaluated.
plicable, date and cause of death is reported along with
the other follow-up data.
Included were all ESRD patients who received HD
Significant enhancements to hemodialysis (HD) have
at some time between January 1, 1981 and December
occurred since the initial development of the technique
31, 1997, the start and conclusion of the period of obser-
[1], and particularly in recent years [2]. Due to increased
vation, respectively. Patients were classified by gender,
attention to dialysis adequacy, the average dose of dial-
PRD, and race (Black, Caucasian, First Nations, Orien-
ysis has increased [3–6]. Major advances have occurred
tal, Asian Indian, Other). Follow-up time on hemodialy-
in membrane technology, as dialyzers with greater bio-
sis was computed for each patient, with person-years
compatibility, greater flux and higher clearance rates have
(PY) of follow-up classified by age (#14, 15–44, 45–64,
been developed [7–10]. Erythropoietin was introduced
65–74, $75), calendar period (1981–1985, 1986–1989,
to combat anemia [11, 12], while bicarbonate replaced
1990–1993, 1994–1997), and follow-up time (1-year inter-
acetate as the dialysate most commonly employed [13].
vals). Naturally, age, calendar period, and follow-up in-
Despite such major changes in HD methods and prac-
terval were dynamic variables in that patients could con-
tribute PYs to more than one category, as they were
followed longitudinally through the period of observa-Key words: dialysis, end-stage renal disease, epidemiology, renal fail-
ure, survival. tion. Hence, our analysis accounted for the migration of
patients through age, calendar period and follow-up time 2000 by the International Society of Nephrology
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Table 1. Baseline characteristics of patients initiating hemodialysiscategories. Patients who received a kidney transplant
in Canada during 1981–1997
were censored at the date of transplantation.
Characteristica N %bMortality rates were computed as the ratio of deaths
Age groupto person-time within each cross-classification defined
#14 327 1.1by age, sex, race, follow-up time window and calendar
15–44 6917 24.1
period. Deaths were allocated to the dialytic modality 45–64 10,450 36.4
$65 11,006 38.3received at the time of death. That is, deaths were only
Gendercounted against HD if the patient was receiving HD at
Female 11,107 38.7
the time of death. Poisson regression [19, 20] was used to Male 17,589 61.3
Unknown 4 0.0compare calendar-period-specific mortality rates while
Raceadjusting simultaneously for all previously listed covari-
Asian Indian 514 1.8
ables. That is, the logarithm (base e) of the mortality Black 634 2.2
Caucasian 22,674 79.0rate was modeled as a linear function of parameters
First Nations 1313 4.6representing each variable. The mortality rate ratio (RR,
Oriental 1086 3.8
i.e., death rate for each calendar period, relative to the Other 2479 8.6
Calendar periodarbitrarily chosen reference period: 1981–1984) served
1981–1985 4460 15.5as the parameter of interest.
1986–1989 5555 19.4
In terms of supplementary analysis, separate Poisson 1990–1993 7678 26.8
1994–1997 11,007 38.4regression models were fitted by age and diabetes status
Primary renal diagnosisin order to examine the consistency of the trend in ad-
Diabetes mellitus 6199 21.6
justed mortality rates across patient subpopulations. Fol- Glomerulonephritis 4731 16.5
Polycystic kidney disease 1690 5.9low-up time window-specific models were also fitted.
Renal vascular disease 4849 16.9Trends over time for major causes of death (COD) were
Other 11,231 39.1
examined to assess the degree of uniformity in COD- Total 28,700 100
specific trends, and in order to add context to observed a Patients classified based on date of renal replacement therapy initiation
b Percentages may not add to 100 due to roundingtrends in all-cause mortality. A model was also fitted
with both “calendar period” and “cohort” variables, for
the purpose of determining whether the trends in mortal-
ity rates were strongest cross-sectionally across calendar
experienced a greater than two-fold increase. Corre-time or longitudinally within patient cohorts. Trends in
spondingly, the mean age at HD-initiation increasedtransplant rates among HD patients were also evaluated
steadily over time, from 49.2 in 1981–1985 to 59.5 inin order to further assess changes in the HD case-mix.
1994–1997. The percentage of patients with diabetes as
a PRD more than doubled during the period of observa-
RESULTS tion, while that for glomerulonephritis reduced by greater
than one half.In Table 1, baseline characteristics are presented for
In total, we observed 10,685 deaths on hemodialysisthe 28,700 patients who received hemodialysis at some
during a total of 52,583 person-years, for an overall mor-time between 1981 and 1997. Approximately 38% of the
tality rate of 203.2 per 1000 PY (Table 3). UnadjustedHD population initiated HD after age 65 years, while
mortality RRs were significantly increased for 1986–1989,about 1% of patients were children aged 14 years and
1990–1993 and 1994–1997 relative to 1981–1985. However,under. The male : female split was approximately 61 :
a strong monotone decreasing trend was observed with39. The majority of patients were Caucasian (79%), while
respect to the covariable-adjusted mortality RRs. Signifi-First Nations patients comprised 5% of the HD popula-
cant reductions were witnessed for the 1990–1993 (RR 5tion. Approximately 22% of patients were diabetic. The
0.90; 95% CI: 0.83–0.96) and 1994–1997 (RR 5 0.74;number of patients initiating HD increased greatly during
0.69–0.80) calendar periods relative to 1981–1985.our period of observation. During the most recent calen-
A more detailed examination of the trend in adjusteddar period, 1994–1997, slightly over 11,000 patients be-
HD patient mortality is depicted in Fig. 1. Here, 8 calen-gan HD.
dar periods are employed, with 1981–1983 serving as theThe hemodialysis patient age and PRD distributions
reference and the remainder of the observation periodby calendar period are displayed in Table 2. The percent-
broken into 2-year intervals. The improvement in HDage of patients in each age group decreased over calendar
mortality does not appear to level off. In fact, the declinetime, with the exception of the $65 years category. The
in RR, steady between 1984 and 1995, strengthens appre-fraction of patients in the 15–44 years age group was
ciably during the 1995–1996 period.reduced by one half during 1994–1997 compared to 1981–
1985, while the percentage in the $65 years age group Covariable-adjusted mortality rate ratios are pre-
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Table 2. Distributiona by age and primary renal diagnosis for patients initiating hemodialysis in Canada, 1981–1997
Characteristicb 1981–1985 1986–1989 1990–1993 1994–1997
Age group
#14 2 1 1 1
15–44 36 28 22 18
45–64 41 38 36 34
$65 22 32 40 47
Mean age (years) 49.2 53.7 56.8 59.5
Primary renal diagnosis
Diabetes 13 18 22 27
Glomerulonephritis 27 19 15 12
Polycystic kidneys 8 7 6 5
Vascular 13 15 18 19
Other 41 41 39 38
a Distribution is expressed in percent. Percentages may not add to 100 due to rounding
b At date of renal replacement therapy initiation
Table 3. Hemodialysis mortality rates and rate ratios by calendar period
Adjustedc
Calendar Unadjusted Unadjusted
period Deaths PY rate per 1000 RRa 95% CIb RR 95% CI
1981–1985 941 5259 178.9 1 – 1 –
1986–1989 1953 9581 203.8 1.14 1.03–1.25 0.95 0.88–1.03
1990–1993 3178 14,614 217.5 1.22 1.11–1.33 0.90 0.83–0.96
1994–1997 4613 23,129 199.5 1.11 1.02–1.22 0.74 0.69–0.80
1981–1997 10,685 52,583 203.2
a RR 5 mortality rate ratio
b CI 5 confidence interval
c RR estimated using Poisson regression, and adjusted for age, gender, race, primary renal diagnosis and follow-up time
Table 4. Adjusted hemodialysis mortality rate ratios by calendar
period and patient subpopulation
Patient
subpopulation Calendar period RRa 95% CIb
Non-diabetics 1981–1985 1 –
Age ,65 1986–1989 1.01 0.91–1.13
1990–1993 1.01 0.91–1.12
1994–1997 0.88 0.79–0.98
Non-diabetics 1981–1985 1 –
Age $65 1986–1989 0.88 0.78–1.00
1990–1993 0.83 0.74–0.93
1994–1997 0.70 0.63–0.79
Diabetics 1981–1985 1 –
Age ,65 1986–1989 0.81 0.64–1.02
1990–1993 0.73 0.59–0.91
Fig. 1. Mortality rate ratios (RR), enclosed by 95% confidence inter- 1994–1997 0.54 0.44–0.67
vals (CI) for hemodialysis patients in Canada, 1981–1997. Calendar Diabetics 1981–1985 1 –
time was divided into 8 subintervals, with 1981–1983 serving as the Age $65 1986–1989 1.02 0.72–1.46
reference period (RR 5 1, fixed). RRs were estimated using Poisson 1990–1993 0.81 0.58–1.14
regression, and adjusted for age, gender, race, primary renal diagnosis 1994–1997 0.65 0.47–0.91
and follow-up time. a RR 5 rate ratio, estimated using Poisson regression and adjusted for age,
gender, race, primary renal diagnosis, and follow-up time
b CI 5 confidence interval
sented by age and diabetes status in Table 4. The strong-
est gradient of decrease was experienced by diabetics
non-diabetics aged ,65 years and diabetics aged $65aged ,65 years, with 1994–1997 adjusted mortality rates
years, the mortality reduction attained statistical signifi-being reduced by 46% relative to 1981–1985. For non-
cance only for the 1994–1997 calendar period. Literallydiabetics aged ,65 years and diabetics aged ,65 years,
no decrease in adjusted death rates was observed duringthe decrease in adjusted mortality rates was statistically
significant for the two most recent calendar periods. For 1986–1989 and 1990–1993 (RR <1 for each) among non-
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Fig. 2. Mortality rate ratios (RR) and 95% confidence intervals (CI) for hemodialysis patients by follow-up time interval in Canada, 1981–1997.
Calendar time was divided into 4 subintervals, with the 1981–1985 period serving as the reference (RR 5 1, fixed). Each panel pertains to a
separate time window following initiation of renal replacement therapy. RRs were estimated using Poisson regression, and adjusted for age, gender,
race, primary renal diagnosis.
Table 5. Distribution of causes of death by calendar period indiabetics aged ,65 years. Within the diabetic/$65 years
Canadian hemodialysis patients, 1981–1997a
category, statistical power is limited, as evidenced by the
Cause of death 1981–1985 1986–1989 1990–1993 1994–1997width of the confidence intervals.
CVDb 41 40 39 36Adjusted rate ratios are displayed by follow-up time
Infection 9 9 9 8in Fig. 2. A steady decline in mortality was observed
Vascular 7 7 6 7
during the first year post-initiation of RRT, with RRs Social 10 14 16 19
Other/unspecified 33 30 31 29significantly reduced for the 1990–1993 and 1994–1997
calendar periods (Fig. 2A). In follow-up year two, little a Distribution is expressed as a percent
b CVD 5 cardiovascular diseasechange in mortality occurred for the first two calendar
periods, although a significantly reduction was observed
for 1994–1997. During year 3, the decrease in RR barely
failed to reach significance for 1994–1997 and was absent continue therapy) increased greatly, from 10% in 1981–
for earlier periods (Fig. 2C). No discernible trend in 1985 to 19% during 1994–1997.
mortality was observed during the fourth year of follow- COD–specific adjusted mortality rate ratios are listed
up (Fig. 2D). in Table 6. The strongest decrease was observed for
The cause-of-death distribution is listed by calendar deaths due to CVD, which accounted for 38% of the total
period in Table 5. Within each period, cardiovascular number of deaths. Strong decreases also occurred with
disease (CVD) was the most frequent COD, the percent- respect to deaths due to infection and vascular disorders.
age falling slightly from 41% in 1981–85–36% during During the 1994–1997 period, RRs were significantly
1994–97. Generally, the distribution of deaths by COD decreased for each COD category, with the exception
was quite stable over time. However, the percentage of deaths due to social causes, which showed a significant
increase for all periods subsequent to 1981–1985.of deaths due to social causes (e.g., suicide, refusal to
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Table 6. Hemodialysis mortality rate ratios for selected causes of death (COD) by calendar period
1981–1985 1986–1989 1990–1993 1994–1997
Cause of death N % RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
CVDa 4073 38.1 1 0.91 0.81 0.62
(0.82, 1.00) (0.73, 0.89) (0.56, 0.68)
Infection 933 8.7 1 0.94 0.92 0.78
(0.80, 1.10) (0.79, 1.07) (0.67, 0.90)
Vascular 725 6.8 1 0.89 0.80 0.78
(0.75, 1.04) (0.68, 0.93) (0.68, 0.91)
Socialb 1737 16.3 1 1.24 1.27 1.20
(1.07, 1.44) (1.10, 1.46) (1.05, 1.38)
Other/unspecified 3217 30.1 1 0.87 0.88 0.72
(0.78, 0.98) (0.79, 0.97) (0.65, 0.80)
All causes 10,685 100 1 0.95 0.90 0.74
(0.88, 1.03) (0.83, 0.96) (0.69, 0.80)
a CVD is cardiovascular disease
b Suicide, refusal to continue therapy, etc
Table 7. Adjusted mortality rate ratios by patient cohort and increased for more recent calendar periods. The im-
calendar period hemodialysis patients in Canada, 1981–1997
provement was concentrated within the first year of fol-
Patient cohorta RRb 95% CIc Calendar perioda RRb 95% CIc low-up. Among causes of death, the improvement in
1981–1985 1 — 1981–1985 1 — mortality was strongest for CVD-attributable deaths.
1986–1989 1.10 1.03–1.18 1986–1989 0.89 0.82–0.97 Among patient subpopulations, the mortality decrease
1990–1993 1.12 1.04–1.21 1990–1993 0.81 0.73–0.88
was most pronounced for diabetics aged ,65 years, and1994–1997 0.96 0.88–1.15 1994–1997 0.71 0.64–0.79
least pronounced for non-diabetics aged ,65 years.a Patients classified based on date of initiation of HD
b RR 5 rate ratio, estimated using Poisson regression and adjusted for age, The decrease in HD mortality is likely related to tech-
gender, race, primary renal diagnosis, and follow-up time nical and therapeutic advances in HD that took placec CI 5 confidence interval
during the period of observation. In terms of equipment,
the sophistication of dialysis machines continues to in-
crease over time. Membranes have been developed
In Table 7, results are presented for a regression model which are more biocompatible, while high-efficiency and
that contained terms for calendar time in the “period” high-flux dialyzers permit elevated rates of clearance
and “cohort” sense. The cohort variable was defined [7–10]. A shift from acetate to bicarbonate dialysate has
once, and only once, per patient, and represents the also occurred [13]. Increased attention has been ac-
calendar time interval during which HD was initiated. corded to dialysis adequacy, which has led to increases
As stated, patients could contribute PYs to more than in the average dose of dialysis [3–6], and ultimately to
one calendar “period” variable during their follow-up the formal establishment of guidelines of HD care [21].
time. Only the “period” RRs indicate significant de- Based on data from the United States Renal Data System
creases in adjusted mortality. (USRDS) [22], it has also been hypothesized that pa-
Results in Table 8 pertain to a regression model where tients are now initiating RRT earlier in the disease pro-
transplantation replaced death as the end-point of inter-
cess than in the past [23]. Nutrition and the management
est. Only first renal transplants were included. Relative
of comorbid illnesses have also improved. Each of theto 1981–1985, covariable-adjusted transplant rates were
above-listed factors has been found to influence patientsignificantly increased during the 1986–1989 period
outcomes to various degrees. The extent to which each(RR 5 1.17). However, significant decreases were ob-
of these factors is associated with the decline in HD mor-served during 1990–1993 (RR 5 0.86) and 1994–1997
tality is unclear since data on practice patterns among(RR 5 0.70). There was great discrepancy between the
Canadian nephrologists is sparse.unadjusted and covariable-adjusted RRs in terms of
Few studies have explicitly evaluated mortality trendsmagnitude and, for 1986–89, direction.
for HD or other RRTs. Based on data from the Michigan
Kidney Registry (MKR), Wolfe et al reported that in-
DISCUSSION center HD adjusted log (death rates) experienced a sig-
nificant 6% average annual increase between 1980 andWe observed a statistically significant decrease in he-
1987 [14]. In a subsequent study also based on MKRmodialysis mortality rates in Canada during the 1981–
data, Nelson et al found an increase of 4% per year (P ,1997 period, after adjustment for age, gender, race, pri-
0.06) in adjusted log (RR) among HD patients duringmary renal diagnosis and follow-up time. The decline
did not show signs of leveling off, and appears to have the 1980–1989 period [15]. However, the Morbidity,
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Table 8. Adjusted transplantationa rate ratios for hemodialysis patients by calendar period
Adjustedd
Unadjusted Unadjusted
Calendar period Kidneya transplants Person-years rate per 1000 RRb 95% CIc RR 95% CI
1981–1985 1,153 5,259 219.2 1 — 1 —
1986–1989 1,799 9,581 187.8 0.86 0.78–0.94 1.17 1.10–1.24
1990–1993 1,655 14,614 113.5 0.52 0.47–0.57 0.86 0.81–0.92
1994–1997 1,797 23,129 77.7 0.35 0.32–0.39 0.70 0.66–0.75
1981–1997 6,404 52,583 121.8
a Only first renal transplants were included
b RR 5 transplant rate ratio
c RR estimated using Poisson regression and adjusted for age, gender, race, primary renal diagnosis, and follow-up time
d CI 5 confidence interval
Mortality and Prescription of Dialysis Symposium [24] any other COD category, were significantly increased
for each calendar period subsequent to 1981–1985. Sub-dramatically altered HD prescription practices in the
U.S. and elsewhere. Correspondingly, more recent data group analysis revealed that HD mortality did not sig-
nificantly decrease among nondiabetic patients aged ,65from the U.S. are more encouraging. Based on the
USRDS database, Wolfe et al [16] and Port et al [17] years. It is noteworthy that this subgroup, unlike all oth-
ers, experienced significantly increased adjusted rates ofobserved significant reductions in first- and second-year
HD mortality rates between 1985 and 1995. Similar to death due to social causes during the 1986–1989 (RR 5
1.84), 1990–1993 (RR 5 2.24) and 1994–1997 (RR 5the current investigation, the USRDS results indicate
that the improvement in mortality is stronger in year 1 2.11) calendar periods (data not tabulated). In fact, RRs
for deaths due to social causes were increased, albeitthan in year 2 of follow-up. Unlike our study, Port et al
[17] had available data on various treatment parameters, much less dramatically, among non-diabetics aged $65
years, while decreasing trends were observed for diabet-including dialysis dose, treatment time, membrane type
and dialysate buffer. The authors report increases in ics (data not shown). Explanations for such results are
unavailable, and warrant future study.average dialysis dose, use of synthetic membranes and
use of bicarbonate dialysate, and attribute the majority of Another recent investigation based on the CORR da-
tabase examined trends in mortality on peritoneal dial-the mortality reduction to changes in dose and dialysate.
Registry data are invaluable in the context of examin- ysis (PD) [25]. Generally, findings were similar in that
significant decreases were observed for adjusted PDing trends in outcomes over calendar time, since the
cost of following a sufficient number of patients over a mortality. Among CODs, the overall improvement was
mostly driven by CVD mortality. As well, the effect wassufficiently long time period to discern meaningful trends
would clearly be prohibitive. However, registry data do concentrated early in the follow-up period. However,
the HD and PD results differed in a few important ways.suffer some liabilities. Although the Registry is complete
in the sense that all patient records are forwarded by all Although diabetics aged ,65 years experienced the
greatest mortality decrease over time, no appreciableCanadian renal centers, data are not validated or au-
dited. However, it is extremely doubtful that data quality difference in the mortality trends by patient subpopula-
tion was observed. For PD, no increase in rates of deathdiffered between calendar periods in such a way as to
bias our results. Comorbidity data were available, but due to social causes were observed. Although mean age
and diabetes prevalence increased over time for bothnot utilized since they were only collected for patients
initiating RRT from 1988 onward. If anything, this would the HD and PD studies, unlike the current results, the
unadjusted mortality RRs were comparable to the cova-be expected to result in under-estimation of the improve-
ment in mortality. That is, since we find no decrease in riable-adjusted RRs in the PD study.
In both the HD and PD studies, rates of outcomesunadjusted mortality, but observe a significant decrease
upon adjustment for available covariables, one would other than death were considered as possible explana-
tions for the decreasing mortality trend. Since techniqueexpect that more refined adjustment would, if anything,
produce an even stronger effect. When models were failure and transplantation could “compete” against
mortality in such a way that artificial improvements infitted based on only patients from 1988 to 1996, calendar
time RRs were similar when adjusted, and not adjusted, mortality appear, much attention in the PD study was
directed towards evaluating trends in other forms offor comorbidity (data not shown). Although the comor-
bidity profile for patients would be expected to worsen transfer from PD (i.e., technique failure, transplanta-
tion). Transplant rates were, actually, increased, while awith calendar time, the worsening is, likely, largely cap-
tured by age and PRD. decreasing trend in technique failure rates was observed,
thus eliminating both as potential sources of bias. UponRates of HD mortality due to social causes, unlike
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more detailed examination, technique failure RRs for period. The mortality decline is primarily related to the
CAPD alone were found to be significantly reduced dur- several improvements in HD methods and practices
ing the 1990s relative to the 1980s (Schaubel et al, manu- which occurred during that period. Since the observed
script in preparation). Naturally, due to its rarity, HD decreasing mortality trend did not appear to level off,
technique failure would not be expected to induce bias and since further improvement in dialysis equipment and
in observed mortality trends. However, unlike PD, trans- technology are possible and even predicted [26, 27], con-
plant rates from HD were significantly decreased for tinued reductions in HD mortality can likely be expected.
both the 1990–1993 and 1994–1997 periods. Analysis of
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